History of Peptide Synthesis: Fischer to Merrifield

In 1907, Emil Fischer needed years of painstaking solution chemistry to assemble an 18-residue polypeptide by hand. By 1969, a machine in Bruce Merrifield's laboratory had built ribonuclease A, 124 residues, in a matter of weeks. The history of peptide synthesis is really the story of how that gap closed.

Who invented peptide synthesis, and how did the method develop?

No single chemist invented it. Theodor Curtius and Emil Fischer established peptide bond chemistry between 1881 and 1907, Max Bergmann and Leonidas Zervas made it controllable with the carbobenzoxy protecting group in 1932, Vincent du Vigneaud synthesised the first peptide hormone in 1953, and R. Bruce Merrifield introduced solid phase peptide synthesis in 1963, work recognised with the 1984 Nobel Prize in Chemistry.

The popular shorthand, that Merrifield invented peptide synthesis, gets the credit backwards. Chemists had been building peptides in solution for six decades before him. What Merrifield invented was a way to skip isolation and purification after every single coupling, which is precisely where the older approach collapsed. This page walks the timeline from Fischer to Merrifield to modern automated SPPS, compares the eras side by side, and explains what that history still means for anyone verifying a research peptide today.

Who invented peptide synthesis, and when did the field actually begin?

The earliest claim belongs to a chemist most people have never heard of. Theodor Curtius prepared benzoylglycylglycine in 1881, generally recognised as the first synthetic compound containing a peptide bond, but the benzoyl group could not be removed cleanly, so he never held a free dipeptide in his hands. That came in 1901, when Emil Fischer and Ernest Fourneau obtained glycylglycine by hydrolysing the diketopiperazine of glycine. Fischer proposed the name peptide the following year.

Understanding why this took so long means understanding the chemistry. A peptide bond is an amide link between the alpha-carboxyl group of one amino acid and the alpha-amino group of the next. Simple to describe, brutal to control. Every amino acid carries both reactive groups at once, so mixing activated amino acids without restraint produces a random polymer rather than a defined sequence, and any chiral alpha-carbon can racemize during activation. Every chapter in the history of peptide synthesis is an answer to that one control problem: how do you force exactly one bond to form, in exactly one direction, without scrambling stereochemistry?

It isn't. It took roughly eighty years of incremental chemistry to make it look that way.

What did Emil Fischer actually achieve with peptides?

Fischer did two things that mattered permanently: he made defined peptides, and he used them as evidence about protein structure. Working with acid chloride and ester activation, his group reached an octadecapeptide in 1907 built from fifteen glycine and three leucine residues. The compound gave a positive biuret reaction and was cleaved by pancreatic enzymes, which argued strongly that proteins are long chains of amino acids joined by amide bonds. That was the polypeptide theory, advanced independently by Fischer and Franz Hofmeister in 1902, and Fischer's synthetic chains were its physical proof.

Worth separating out, because it confuses people constantly: Fischer received the Nobel Prize in Chemistry in 1902 for his work on sugar and purine syntheses, not for his peptide chemistry. The Emil Fischer peptide work came mostly after the prize.

His methods also show exactly where the wall was. Halogen-based activation was aggressive enough to racemize chiral residues, so glycine-heavy sequences were safer and more tractable. There was no protecting group that could be attached to shield the amino terminus and then removed again without damaging the chain. Each product had to be isolated and recrystallised. Solubility fell as chains lengthened. Fischer is said to have doubted that chemists would ever reach proteins by synthesis, and with the tools he had, he was right.

How did protecting groups turn peptide chemistry into a repeatable process?

The hinge of the entire history of peptide synthesis is 1932, when Max Bergmann and Leonidas Zervas introduced the carbobenzoxy group, now usually written as benzyloxycarbonyl, Cbz or Z. It did what nothing before it could: it blocked the alpha-amino group during coupling, then came off by catalytic hydrogenolysis under mild, neutral conditions that left the peptide bonds and the stereocentres intact. Reversible protection converted peptide synthesis from a series of one-off experiments into a repeatable cycle.

The rest of the solution-phase era filled in the missing pieces. Tert-butyloxycarbonyl, the Boc group, arrived in the mid-1950s and could be removed with acid rather than hydrogen, giving chemists a second, chemically different option. In 1955 John Sheehan and George Hess described dicyclohexylcarbodiimide, DCC, a carbodiimide that activates the carboxyl group in situ so a coupling no longer requires a preformed acid chloride. In 1970 Wolfgang Koenig and Rolf Geiger added 1-hydroxybenzotriazole, HOBt, as an additive that suppresses racemization during carbodiimide coupling.

Taken together, these advances produced the concept that still governs the field: orthogonality. Protecting groups on the chain end, on the side chains and at the anchor point must each be removable by a mechanism that leaves the others untouched. Acid-labile, base-labile, hydrogenolysis-labile. Choose a non-orthogonal combination and the chain falls apart halfway through assembly.

Why was du Vigneaud's oxytocin synthesis the real turning point?

Because it answered a biological question, not just a chemical one. In 1953 Vincent du Vigneaud's group at Cornell completed the synthesis of oxytocin, a nonapeptide containing an intramolecular disulfide bridge between two cysteine residues, and the synthetic material reproduced the biological activity of the natural hormone. That result confirmed the proposed structure and demonstrated that a hormone could be built from scratch. Du Vigneaud received the Nobel Prize in Chemistry in 1955 for his work on biologically important sulphur compounds, especially the first synthesis of a polypeptide hormone.

Insulin then showed the ceiling. Through the mid-1960s, groups in Aachen led by Helmut Zahn, in Pittsburgh led by Panayotis Katsoyannis, and in Shanghai, which reported crystalline bovine insulin in 1965, each assembled the 51-residue two-chain hormone. The syntheses worked. The overall yields were punishing.

Here is the arithmetic that drove everything afterwards. In classical solution-phase work, every coupling is followed by isolation, and every isolation loses material. A step that succeeds nine times out of ten is excellent chemistry, and it still leaves almost nothing recoverable after fifty consecutive cycles. Long sequences weren't limited by the bond-forming chemistry. They were limited by purification.

What is Merrifield solid phase peptide synthesis, and how does it work?

Merrifield solid phase synthesis anchors the C-terminal amino acid to an insoluble polymer bead and extends the chain while it stays covalently attached, so excess reagents and soluble byproducts are removed by filtration and washing rather than by recrystallisation or chromatography. R. Bruce Merrifield published the idea in the Journal of the American Chemical Society in 1963, in a paper titled 'Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide'. The support was chloromethylated polystyrene cross-linked with divinylbenzene.

The cycle is deliberately monotonous: remove the temporary protecting group from the chain's amino terminus, wash, couple the next activated residue, wash, repeat. At the end, cleave the finished chain from the resin and strip the side-chain protection. Because the peptide never leaves the bead, the chemist can wash away failure instead of chasing it through a column.

Two details get lost in most summaries. First, the bead is not a surface. In a swelling solvent such as dimethylformamide or dichloromethane, the cross-linked polystyrene expands several-fold into a solvated gel, and the overwhelming majority of growing chains sit inside that matrix, which is why solvation behaviour matters far more than bead surface area. Second, the genuine innovation was economic rather than chemical. In solution, you cannot drive a coupling with a large excess of activated amino acid, because separating the excess is the very problem you're trying to solve. On resin, excess reagent costs money, not purity. Merrifield made brute force affordable.

Why did Bruce Merrifield win the Nobel Prize in Chemistry?

The Bruce Merrifield Nobel Prize came in 1984, awarded to him alone, for his development of methodology for chemical synthesis on a solid matrix. The citation is broader than peptides on purpose, and that breadth is the point.

Between the 1963 paper and the prize, Merrifield's group demonstrated what the method made possible. With John Stewart he built an automated instrument in the mid-1960s that ran the deprotection, coupling and washing steps under machine control, making peptide assembly a programmable process for the first time. In 1969, with Bernd Gutte, the laboratory reported the total synthesis of ribonuclease A, a 124-residue enzyme, and the synthetic material showed enzymatic activity. A chain that long simply was not reachable by classical solution methods in any practical timeframe.

The principle then escaped its original field. Solid-support strategy underpins modern oligonucleotide synthesis, combinatorial chemistry and solid-phase organic synthesis generally. Studying the history of peptide synthesis makes clear that the prize rewarded a general method for building sequence-defined molecules, not a single peptide.

Boc or Fmoc: how did the two SPPS strategies diverge?

The original Merrifield chemistry paired Boc protection at the amino terminus with benzyl-based side-chain protection. Each cycle used trifluoroacetic acid to remove the Boc group, and the final cleavage required anhydrous hydrogen fluoride, which demands specialised apparatus and skilled handling. The strategy works, but it is graduated, not orthogonal: both the temporary and the permanent protection are acid-labile, just at different strengths.

Louis Carpino and Grace Han described the 9-fluorenylmethoxycarbonyl group, Fmoc, in 1970. Fmoc is base-labile, cleanly removed by piperidine in dimethylformamide, which makes it genuinely orthogonal to acid-labile side-chain groups and acid-labile linkers. Eric Atherton and Robert Sheppard built that insight into a complete Fmoc-polyamide SPPS system in the late 1970s, and resin chemistry kept pace, with Su-Sun Wang's 1973 linker giving C-terminal acids on mild acid cleavage and amide-forming resins doing the same for C-terminal amides.

Fmoc chemistry now dominates research-scale work, largely because it removes hydrogen fluoride from the workflow and allows real-time monitoring of deprotection. Boc chemistry survives where it still wins: aggregation-prone sequences, certain hydrophobic chains, and some chemical ligation work. Difficult sequences remain difficult in either strategy, usually through beta-sheet aggregation on the resin, which is why pseudoproline dipeptides, backbone amide protection and elevated-temperature coupling exist.

How do the major eras of peptide chemistry compare?

This table maps each era against what it unlocked and where it stalled. It matters because the limitations, not the breakthroughs, explain why the next era happened.

What should you remember from this timeline?

• No one person invented peptide synthesis: Curtius formed the first peptide bond in 1881, and Fischer and Fourneau isolated the first free dipeptide, glycylglycine, in 1901.
• Emil Fischer coined the term peptide in 1902 and reached an 18-residue chain by 1907, but his 1902 Nobel Prize was awarded for sugar and purine chemistry, not peptides.
• The carbobenzoxy protecting group introduced by Bergmann and Zervas in 1932 is the single advance that made stepwise, repeatable peptide assembly possible.
• Vincent du Vigneaud's 1953 synthesis of the nonapeptide oxytocin was the first synthesis of a polypeptide hormone and earned the 1955 Nobel Prize in Chemistry.
• Merrifield solid phase synthesis, published in 1963, replaced purification after every coupling with filtration and washing, and the Bruce Merrifield Nobel Prize followed in 1984.
• Fmoc chemistry, introduced by Carpino and Han in 1970 and developed into a full SPPS system by Atherton and Sheppard, is the strategy behind most research-scale synthesis performed today.

What if the history gets murky in practice?

What if two sources credit different people with inventing peptide synthesis?

Check which claim each source is actually making, because three different firsts get conflated. Curtius made the first peptide bond in a protected compound in 1881, Fischer and Fourneau isolated the first free dipeptide in 1901, and Merrifield invented the first scalable method in 1963. Priority disputes in this field are usually definitional rather than factual, and reputable reviews distinguish between them explicitly.

What if a sequence stalls partway through solid phase assembly?

The usual culprit is on-resin aggregation, not a failed reagent batch. Growing chains can adopt beta-sheet structure inside the swollen resin, burying the reactive amino terminus so incoming activated residues cannot reach it, which shows up as a sudden drop in coupling efficiency at a specific residue. The published remedies involve disrupting that secondary structure: pseudoproline dipeptides, backbone amide protection, different solvation, or elevated-temperature coupling.

What if a certificate of analysis doesn't match the sequence that was ordered?

Treat the analytical data as the primary record and the label as secondary. Mass spectrometry should confirm that the observed molecular mass corresponds to the theoretical mass calculated from the stated amino acid sequence, and HPLC should show a chromatographic profile consistent with a single principal component. A mass discrepancy matching a common deletion or an incomplete side-chain deprotection is a synthesis problem, and it belongs back with the supplier before any research use.

What is the honest verdict on who deserves the credit?

Here's the honest answer: Merrifield earned the fame, and Bergmann and Zervas are the most underrated figures in the entire history of peptide synthesis. Solid phase chemistry is impossible without reversible, selectively removable protection, and that is a 1932 invention, not a 1963 one. Merrifield reorganised a workflow that already worked; carbobenzoxy made the workflow exist at all. The reason one is a household name in chemistry and the others are a footnote is that automation is visible and protecting groups are not. Both belong in the same sentence.

What came after Merrifield, and where is synthesis heading?

Stepwise SPPS has a practical length limit, so the next advance was fragment joining. In 1994 Philip Dawson, Tom Muir, Ian Clark-Lewis and Stephen Kent published native chemical ligation in Science, a chemoselective reaction between a peptide thioester and a second peptide bearing an N-terminal cysteine that forms a native peptide bond in aqueous buffer with the side chains fully unprotected. Kent's group had already completed the total chemical synthesis of HIV-1 protease, 99 residues, in 1989, and ligation turned that kind of result into a general strategy.

Coupling chemistry also kept improving. Uronium and phosphonium reagents such as HBTU, HATU, described by Carpino in 1993, and PyBOP gave faster, cleaner activation with less racemization than carbodiimide alone, and Oxyma-based reagents followed as safer alternatives to benzotriazole additives.

Speed came next. Microwave-assisted SPPS cut cycle times substantially, and continuous-flow systems went further, with work from the Pentelute laboratory at MIT published in 2017 describing a fully automated flow-based approach in which amide bond formation occurs on a timescale of seconds. The current pressure point is solvent. Dimethylformamide and N-methylpyrrolidone dominate the field and carry regulatory and environmental burdens, and a substantial body of green chemistry literature is now devoted to replacing them without sacrificing resin swelling.

What does this history mean for a laboratory sourcing research peptides now?

It means the sequence on the label is a claim, and the analytical data is the evidence. Every method in the history of peptide synthesis produces characteristic failure modes: deletion sequences where a coupling didn't go to completion, truncations, incompletely deprotected side chains, and racemized residues that are chemically invisible to a quick mass check. None of these are exotic. They are the normal consequence of running a cycle dozens of times.

That is why identity verification matters more than brand language. Confirming the CAS number and the molecular identity of a compound before procurement, reviewing a lot-specific certificate of analysis, checking that the measured mass matches the theoretical mass of the stated sequence, and looking at the chromatographic profile are the practical descendants of a century of hard-won methodology.Real Peptides supplies research-use-only compounds and publishes lot certificates of analysis at /coas/.realpeptides.co/coas/) page, which is the record a researcher should be reading rather than the marketing copy. All compounds discussed on this page are sold for laboratory research use only and are not for human consumption.

How we researched this page

This page is built from published literature and official records only, with no first-party experimental work behind any claim. Primary sources include Curtius's 1881 report, Fischer and Fourneau's 1901 dipeptide work, Fischer's 1907 polypeptide paper, Bergmann and Zervas's 1932 carbobenzoxy paper, Sheehan and Hess's 1955 carbodiimide paper, Merrifield's 1963 paper in the Journal of the American Chemical Society, Gutte and Merrifield's 1969 ribonuclease A synthesis, Carpino and Han's 1970 description of the Fmoc group, and Dawson and colleagues' 1994 native chemical ligation paper in Science.

Prize dates, citations and laureate details are taken from Nobel Foundation records and published Nobel lectures for 1902, 1955 and 1984. Method descriptions are cross-checked against peer-reviewed reviews of SPPS development. Where priority is genuinely disputed, as with the first peptide bond versus the first free dipeptide, we state the dispute rather than picking a winner, because the history of peptide synthesis is full of parallel discoveries.

Read the history of peptide synthesis closely and one pattern repeats at every turning point. Fischer was blocked by isolation. Bergmann and Zervas removed a deprotection problem. Du Vigneaud hit the purification wall at nine residues. Merrifield didn't invent a better bond, he invented a way to stop purifying. Flow chemistry and ligation did the same thing again, in different clothes. The bond-forming chemistry has been understood for over a century; nearly every leap since has come from getting rid of a separation step. Whatever comes next will almost certainly follow the same logic.

Which guides go deeper on synthesis, verification and handling?

For the chemistry rather than the chronology, start with what peptide synthesis is, then how peptides are made, the full comparison of synthesis methods and custom peptide synthesis. On structure and nomenclature, see the peptide bond, how amino acids build peptides, reading amino acid sequence codes, D-amino acid substitution and stability and the beginner terminology dictionary. On verification, see HPLC purity analysis, mass spectrometry confirmation, HPLC versus mass spectrometry, the key factors in purity testing, research quality standards, purity grade thresholds compared, endotoxin testing limits, why third-party testing matters and how to read a certificate of analysis. On laboratory handling, see what lyophilized means, lyophilized versus liquid stability, shelf life and inventory planning, storage best practices, freezer versus refrigerator storage, degradation pathways, the factors driving degradation and prevention methods. On labelling and scope, see what research use only means and research versus pharmaceutical grade labels.